A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

Talitha I Verhoef, William K Redekop, Josep Darba, Mary Geitona, Dyfrig A Hughes, Uwe Siebert, Anthonius de Boer, Anke-Hilse Maitland-van der Zee, Rita Barallon, Montserrat Briz, Ann Daly, Elisabeth Haschke-Becher (Co-author), Farhad Kamali, Julia Kirchheiner, Vangelis G Manolopoulos, Munir Pirmohamed, Frits R Rosendaal, Rianne M F van Schie, Mia Wadelius

    Research output: Contribution to journalReview articlepeer-review

    21 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)989-1002
    JournalPHARMACOGENOMICS
    Volume11
    Issue number7
    DOIs
    Publication statusPublished - 2010

    Keywords

    • ORAL ANTICOAGULANT-THERAPY
    • INTERNATIONAL NORMALIZED RATIO
    • WARFARIN THERAPY
    • BLEEDING COMPLICATIONS
    • ATRIAL-FIBRILLATION
    • CYTOCHROME P4502C9
    • ECONOMIC OUTCOMES
    • DOSE REQUIREMENT
    • CYP2C9
    • VKORC1

    Cite this